Peptide therapy on TikTok: gym gains or regulatory gray zone?

What did @bigonial_ actually say?

The short version: @bigonial_ called out another creator for pushing TB-500 ("Tessa Moreland" in the transcript) and IGF-1 LR3 as top muscle-building peptides, and said that framing is marketing nonsense. Their core argument is that TB-500 has too short a half-life to matter, IGF-1 LR3 has no meaningful liver binding and no solid muscle-building evidence, and that "peptides are not meant to build muscle, steroids are." They also took a shot at the physique being shown off, suggesting it wasn't built on peptides.

To their credit, they acknowledged their own financial conflicts, noting they are affiliated with brands but claim they don't push misleading recommendations for commission. That kind of disclosure is rare on TikTok and worth acknowledging.

Does the science back this up?

Mostly, yes, with some important nuance. The claim that IGF-1 LR3 lacks meaningful evidence for significant muscle hypertrophy in healthy humans is well-supported. The TB-500 half-life concern is directionally correct but slightly oversimplified.

IGF-1 LR3 was engineered to have reduced binding affinity to IGF-binding proteins (IGFBPs), which does extend its systemic half-life compared to native IGF-1. But that reduced IGFBP binding also means it circulates without the tissue-targeting that makes native IGF-1 effective. Research in this space is thin. Studies like Barnard et al. (1994, Journal of Endocrinology) examined IGF-1 analogs in animal models, and while there are anabolic signals in vitro, human clinical data on LR3 for muscle hypertrophy in healthy populations is essentially absent from peer-reviewed literature.

TB-500 (a synthetic fragment of Thymosin Beta-4) does have a short active half-life in circulation, though the precise figure varies by route of administration. The evidence base for TB-500 is almost entirely preclinical, focused on wound healing and cardiac repair, not skeletal muscle hypertrophy. Goldstein et al. (2012, Annals of the New York Academy of Sciences) summarized Thymosin Beta-4's regenerative properties without any credible muscle-building application in humans.

What did they get wrong or right?

They got the broad strokes right but overstated a few things. Saying TB-500 has a "20 minute half-life" is not well-sourced. Half-life estimates for Thymosin Beta-4 peptide fragments vary and are not clearly established in human pharmacokinetic studies. That specific number appears to circulate in online bodybuilding forums more than in literature.

The claim that "not a single study" proves IGF-1 LR3 builds significant muscle mass is defensible for human hypertrophy trials, but it overstates certainty. There are animal and in vitro studies showing anabolic activity. The honest framing is: no adequate human evidence, not zero evidence of any kind.

Their point about "Increlex" (mecasermin, the pharmaceutical-grade IGF-1) being the form with real tissue activity is legitimate. Increlex is FDA-approved for severe IGF-1 deficiency and does have documented anabolic effects, though it also carries serious risks including hypoglycemia and intracranial hypertension. It is not an over-the-counter peptide and should not be sourced outside a clinical setting.

The broader argument, that peptides are recovery and signaling tools rather than primary anabolic agents, is the most defensible claim in the video and one the evidence supports.

What should you actually know?

The peptide supplement market runs well ahead of the clinical literature, and that gap is where a lot of the hype lives. Here is what the evidence actually supports.

• IGF-1 LR3 is a research compound. It is not approved for human use by the FDA, and its anabolic effects in healthy adult humans have not been demonstrated in controlled trials.
• TB-500 (Thymosin Beta-4 fragment) has a growing preclinical evidence base for tissue repair and regeneration, particularly in cardiac and wound-healing contexts. Muscle hypertrophy is not among its supported applications.
• Peptides that genuinely influence growth hormone secretion, such as CJC-1295 or ipamorelin, work through the GH axis and have indirect, modest effects on body composition. They are not steroids and should not be marketed as equivalent.
• Anyone sourcing IGF-1 LR3 or TB-500 outside of a licensed clinical program is working with unregulated compounds of unknown purity and dosing accuracy.
• The financial incentives in the peptide content space are real. The creator is right to flag affiliate-driven misinformation, even if they were not immune to a few overclaims themselves.